Dr. Ned Snyder is currently a Professor of Internal Medicine in the Division of Gastroenterology at the University Of Texas Medical Branch (UTMB) in Galveston. After several years in private practice, Dr. Snyder came to UTMB in 2002. He attended undergraduate school at Yale University in New Haven, Connecticut, with a B.A. and History, and received his M.D. degree from UTMB. He did his Medicine internship at the University of Michigan in Ann Arbor, followed by a Medical residency and Gastroenterology fellowship at UTMB. He also completed a fellowship in Liver Disease at Yale. Dr. Snyder was an Assistant Professor at UTMB from 1975-1977, and at that time founded the liver service at UTMB. He then entered private practice, and served on the Active Staff or Consultant Staff of several hospitals and medical centers in Central Texas: Waco, San Antonio, Groesbeck, Clifton, Mexia and Temple. He was chief of gastroenterology at Providence Health Center from 1978-2001, and served as a Clinical Associate Professor with Baylor College of Medicine. Dr. Snyder has received grants from the Southern Medical Association, the National Cancer Institute, Amgen Pharmaceuticals, VSL Pharmaceuticals, the GCRC and the Department of Pathology. He has been an invited lecturer on hepatitis C for various UTMB and Texas courses and organizations. He is a member of Alpha Omega Alpha and received the Mu Delta Best Resident Award in 1973. He is a Fellow of the American College of Physicians and was named as one of the “Best Doctors in America” in 1998. He was Program Director of the Texas Club of Internists Annual State Meeting in 1998, President of the Texas Academy of Internal Medicine in 2002-2003, and Co-Director of the Best of DDW Programs in 2003 and 2004. He has been on various UTMB and departmental committees including: Chairman of the UTMB Program Committee of the Alumni Board of Trustees, Gastroenterology Division representative for the Internal Medicine Third-year Curriculum and the Search Committee for the new Dean of the School of Medicine. He is currently President-elect of the UTMB Alumni Board of Trustees. He currently is co-director of the Gastrointestinal and Nutrition course, and directs the Hepatology service at UTMB.

2008 A Multi-center Randomized Double-Blind, Active Control, 96 Week Phase III Trial of the Efficacy and Safety of Clevudine Compared with Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients with HBeAg negative chronic Hepatitis Due to Hepatitis B Virus. Pharmasset Pharmaceutical Company 2008 A Double-Blind, Randomized, Placebo-controlled, Parallel Group Study of Rimonablant 20 mg daily for the Treatment of Non Diabetic Patients with Non Alcoholic Steatohepatitis, Sanofi Aventis Pharmaceutical 2008 A Double-Blind, Randomized, Placebo-controlled, Parallel Group Study of Rimonablant 20 mg daily for the Treatment of Diabetic Patients with Non Alcoholic Steatohepatitis. Sanofi Aventis Pharmaceutical 2007 A Multi-center Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety if Clevudine Compared with Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients with HBeAg Positive Chronic Hepatitis due to Hepatitis B Virus. Pharmasset Pharmaceutical Company 2008 A Phase 2a Multicenter, Randomized, Controlled, Single-Blind Dose Ranging Study to Evaluate the Safety and Antiviral Effect of SCV-07 in Non-Cirrhotic Subjects with Genotype 1 Chronic Hepatitis C Patients Who Have Relapsed to Previous Treatments. Sci Clone Pharmaceuticals 2007 Proteomic Studies to Determine a Biomarker for Hepatocellular Carcinoma. Technical support Ciphergen, Grant support GCRC. 2006 Capsule Endoscopy versus EGD in the Diagnosis of Esophageal varices. Grant support In-Scope 2006 Immunological Determinants in HCV Infection in African Americans. Grant support from the Center for the Study of Health Care Disparities, UTMB 2005 Secondary prophylaxis of spontaneous bacterial peritonitis with the Probiotic VSL #3. Principal Investigator. Grant support VSL Pharmaceuticals 2002 Present: Serum and Proteomic Markers of Fibrosis in Chronic Hepatitis C. General Clinical Research Center Protocol #595. Principal Investigator Grant support GCRC and Dept of Pathology and Internal Medicine and GRIP Completed Protocols: 1999-2001 Amgen protocol # 980181 : “A clinical study of Infergen in Hepatitis C patients who receive an initial course of therapy with Infergen 9 mcg (12 weeks) and retreatment with Infergen 15 mcg (24 weeks) for non-responders” Co-investigator, supported by Amgen 1998-1999 Amgen protocol # 980102 : “Inductive Therapy using 9 mcg vs 15 mcg of Infergen daily for HCV patients who have failed previous interferon therapy” Co-investigator, supported by Amgen 1977-1980 NCI grants # 0-14548671175 and NO1 CP91037, “Epidemiology of Primary Liver Cancer in Selected Counties of Texas”, Co-Investigator, National Cancer Institute 1977-1978 Southern Medical Association, “Metabolic Liver Disease in Cirrhosis” Chief investigator

1. Snyder, N., Correia, J.P., Conn, H.O. Increased Concurrence of Cirrhosis and Bacterial Endocarditis: A clinical and post mortem study. Gastroenterology 1977; 73: 1107-1113. 2. Snyder, N., Hughes, W. Basal and Calcium stimulated gastroesophageal sphincter pressure in Zollinger Ellison Syndrome. Gastroenterology 1977; 72: 1240-1243. 3. Snyder, N., Besoff, J., Dwyer, J., Conn, H.O. Depressed Cutaneous Hypersensitivity in Alcoholic Hepatitis. American Journal of Digestive Diseases 1978; 23: 353-358. 4. Sherwin, R.S., Fisher, M., Besoff, J., Snyder, N., Conn, H.O., Felig, P. Hyperglucagonemia in cirrhosis: Altered secretion and sensitivity to glucagons. Gastroentrology 1978; 74: 1224-1228. 5. Snyder, N. Encephalopathy in the Cirrhotic patient. Texas Medicine 1978; 74: 48-51 6. Van Deventer, G., Snyder, N., Patterson, M. The superior vena cava syndrome, a complication of the LeVeen shunt. JAMA 1979; 242: 1555-1557. 7. Gajula,L., Raza, S.A., Walser, E.M., Snyder, N. Soloway, R.D. Resonance Arteriography as a Prognostic Index in Patients Considered For Transcutaneous Intrahepatic Portosystemic Shunt (TIPS). Gastroenterology 124: A-662, 2003. 8. Snyder N, Gajula L, Grady J, Luxon B, Lau D, Xiao S-Y, Soloway R, Petersen J. The APRI is a Good Predictor of Hepatic Fibrosis, and May Be Affected By Biopsy Size. Gastroenterology 126: A-304, 2004. 9. Snyder N, Gajula L, Finlay D, Hewlett A, Moparty B, Vittal H, Xiao, S-Y, Lau D T-Y, Soloway R, Petersen J. The APRI is a Good Predictor of Fibrosis in HCV, and May be Enhanced By the Insulin Resistance Index (HOMA-IR). A Prospective Study. Am J Gastroenterol 99; S100-101, 2004. 10. Finlay D, Szauter K, Raju GS, Snyder N. Tuberculous Peritonitis Following Infliximab Therapy. Am J of Gastroenterol.100: 1624-1625, 2005 11. Snyder N, Hawari R, Xiao S-Y, Lau D, Soloway R, Petersen J. What are the Best Cut Offs for the APRI. Gastroenterol 130: A-79 12. Martinez J, Xiao S-Y, Snyder N. Chronic Hepatitis C May Be the Most Common Association for Hepatic Granulomas. Gastroentrol 130: A 284. 13. Snyder N., Gajula L, Xiao S-Y, Grady J, Luxon B, Lau D T-Y, Soloway R, Petersen J. APRI: An Easy and Validated Predictor of Hepatic Fibrosis in Chronic Hepatitis C. J of Clin Gastroenterol. 2006; 40: 535-542. 14. Snyder N, Nguyen A, Gajula L, Soloway R, Xiao S-Y, Lau D, Petersen J. The APRI May Be Enhanced By the Use of the FIBROSpect II in the Estimation of Fibrosis in Chronic Hepatitis C. Clinica Chimica Acta.2007; 381: 119-123.

Address:	301 University Blvd., Galveston, Tx. 77555-0764
Email:	nesnyder@utmb.edu
Office:	409-772-1501